Fostemsavir controls viral load in half of people with highly drug-resistant HIV
ABX464 reduces HIV reservoir but doesn’t delay viral rebound
Symtuza protease inhibitor regimen maintains viral suppression for a year
Long-acting monoclonal antibody effective against multidrug-resistant HIV
Maraviroc matches boosted protease inhibitor treatment over 96 weeks
Boosted darunavir plus lamivudine matches three-drug regimen
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment
Long-acting NRTI shows promise for HIV treatment and PrEP
First protease inhibitor combination pill maintains viral suppression
